Syddansk Universitet Role of radiotherapy fractionation in head and neck cancers ( MARCH ) an updated meta-analysis

Lacas, Benjamin; Bourhis, Jean; Overgaard, Jens; Zhang, Qiang; Grégoire, Vincent; Nankivell, Matthew; Zackrisson, Björn; Szutkowski, Zbigniew; Suwiski, Rafa; Poulsen, Michael; O'Sullivan, Brian; Corvò, Renzo; Laskar, Sarbani Ghosh; Fallai, Carlo; Yamazaki, Hideya; Dobrowsky, Werner; Cho, Kwan Ho; Garden, Adam S; Langendijk, Johannes A; Viegas, Celia Maria Pais; Hay, John; Lotayef, Mohamed; Parmar, Mahesh K B; Aupérin, Anne; van Herpen, Carla; Maingon, Philippe; Trotti, Andy M; Grau, Cai; Pignon, Jean-Pierre; Blanchard, Pierre; MARCH Collaborative Group; Johansen, Jørgen

[1]  J. Pignon,et al.  Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis , 2016, BMC Medical Research Methodology.

[2]  J. Pignon,et al.  Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study , 2016, PloS one.

[3]  P. Pai,et al.  Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial , 2016, Head & neck.

[4]  T. Björk-Eriksson,et al.  Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Patrick Royston,et al.  Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data , 2015, Statistics in medicine.

[6]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[7]  Christopher U. Jones,et al.  Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). , 2014, International journal of radiation oncology, biology, physics.

[8]  Christopher U. Jones,et al.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. , 2014, International journal of radiation oncology, biology, physics.

[9]  K. Ramadas,et al.  Phase 2B Randomized Trial Comparing Concurrent Chemoradiation to 6 Fractions/Week Accelerated Radiation Therapy in Advanced Squamous Cell Carcinomas of Head and Neck , 2013 .

[10]  J. Overgaard,et al.  DAHANCA 9: a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck , 2013 .

[11]  Pierre Blanchard,et al.  Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Chitapanarux,et al.  Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer , 2013, Journal of radiation research.

[13]  Suresh C. Sharma,et al.  Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  V. Grégoire,et al.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.

[15]  J F Tierney,et al.  A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. , 2011, Journal of clinical epidemiology.

[16]  C. Grau,et al.  Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. , 2010, The Lancet. Oncology.

[17]  C. Leemans,et al.  Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group. , 2010 .

[18]  M. Parmar,et al.  Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. , 2010, International journal of radiation oncology, biology, physics.

[19]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  S. Sharma,et al.  Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[21]  P. Warde,et al.  Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  M. Tsukuda,et al.  Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) , 2007, Cancer Chemotherapy and Pharmacology.

[23]  J. Langendijk.  The dutch head and neck cancer cooperative study group (NWHHT-SG) , 2007 .

[24]  B. Maciejewski,et al.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. , 2006, International journal of radiation oncology, biology, physics.

[25]  Brian O'Sullivan,et al.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis , 2006, The Lancet.

[26]  J. Bourhis,et al.  Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Shouman,et al.  A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. , 2005, Journal of the Egyptian National Cancer Institute.

[28]  M. Sormani,et al.  Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. , 2003, International journal of radiation oncology, biology, physics.

[29]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[30]  A. Garden,et al.  Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[31]  H. Bartelink,et al.  Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. , 2002, European journal of cancer.

[32]  A. Begg,et al.  Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation , 2002, British Journal of Cancer.

[33]  G. Sanguineti,et al.  Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck , 2001, Cancer.

[34]  L. Peters,et al.  A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study , 2001 .

[35]  J. Naude,et al.  Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[37]  C. Lengeler,et al.  Language bias in randomised controlled trials published in English and German , 1997, The Lancet.

[38]  J. Horiot,et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  L. Weir,et al.  A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[41]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[42]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[43]  K. Dickersin,et al.  Publication Bias: The Problem That Won't Go Away , 1993, Annals of the New York Academy of Sciences.

[44]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[45]  H. Awwad,et al.  Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  S Schraub,et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[48]  C. Rasch,et al.  Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. , 2016, European journal of cancer.

[49]  venlig hilsen,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck : DAHANCA 6 and 7 randomised controlled trial , 2016 .

[50]  E. Chung,et al.  A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  J. Stockman.  Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer , 2012 .

[52]  H. Yamazaki,et al.  Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. , 2006, International journal of radiation oncology, biology, physics.

[53]  R. Macedonia.  Altered and Conventional Fractionated Radiotherapy in Locoregional Control and Survival of Patients with Squamous Cell Carcinoma of the Larynx, Oropharynx, and Hypopharynx , 2006 .

[54]  V. Torri,et al.  Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. , 2003, International journal of radiation oncology, biology, physics.

[55]  A. Serafin,et al.  A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  D. Arthur,et al.  42 Standard once-daily versus thrice-daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: Preliminary results of a prospective randomized trial , 1995 .

[57]  L. Souhami,et al.  Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[58]  T. Pajak,et al.  Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). , 1987, International journal of radiation oncology, biology, physics.